- Home
- AGMH vs PPCB Comparison
AGMH vs PPCB Comparison
Compare AGMH & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGMH | PPCB |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.6M |
| IPO Year | 2017 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AGMH | PPCB |
|---|---|---|
| Price | $0.60 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 171.2K |
| Earning Date | 10-20-2026 | 09-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.06 |
| 52 Week High | $5.77 | $6.79 |
Technical Indicators
Market Signals| Indicator | AGMH | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 34.16 | 34.52 |
| Support Level | $0.48 | $0.17 |
| Resistance Level | $1.38 | $1.29 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 5.44 | 15.59 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is a technology company engaged in technology hardware research and development, manufacturing, assembly, and sales. Its core business segments include research and development of blockchain-oriented ASIC chips, production of high-end crypto miners for Bitcoin and other cryptocurrencies, and Fintech software services. The Company mainly derives revenue from the sales of cryptocurrency mining machines and standardized computing equipment.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.